The Abbott Pandemic Defense Coalition is working nonstop at the front lines of virus surveillance and prevention to help stop outbreaks before they become pandemics.
Abbott Laboratories (NYSE: ABT) has generally been a good investment to hold over the years. Is Abbott a bad-news buy that could turn things around in 2023, or has this once-safe healthcare stock become too risky of an investment to be holding right now? Last month, Abbott reported its fourth-quarter and year-end results for 2022.
No matter which way the market goes, the payouts of companies with decades of dividend growth behind them tend to go in one direction: up. Abbott Laboratories' (NYSE: ABT) 50-year dividend growth streak makes it one of just 43 Dividend Kings. With 113,000 employees and a presence in more than 160 countries, Abbott is among the largest healthcare companies in the world.